Bill Harriman, Ph.D.

Vice President, Antibody Discovery at Ligand Pharmaceuticals

Speaker

Bill received his graduate training in immunology at UCSF and has held research director positions in biotech and pharma companies. His primary focus has been the invention, development, and use of new technology for antibody discovery. In 2008 Bill co-founded Crystal Bioscience and became its CSO with the goal of creating the most diverse and effective antibody repertoires possible from wild-type and transgenic animal systems. Ligand acquired Crystal Biosciences in October 2017.